Leronlimab vs Maraviroc

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: CCR5 co-receptor · full HIV pipeline

Leronlimab

Developed by CytoDyn

Phase 2/3 in HIVmonoclonal antibody
Weak signal

NCT02859961 · Phase 2/3 · completed

Although participants were randomized to dose groups, the study was open-label with no blinding and had no placebo or active-drug control arm - all arms received leronlimab, just at different doses, so there was no true comparator to establish efficacy against. The primary result was reported as simple percentages per dose group with no significance testing, and over half of enrolled participants discontinued before week 48, so this cannot be read as controlled evidence that leronlimab prevents virologic failure better than an alternative.

Reported efficacy

Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77% (met)

Result source: NCT02483078

Maraviroc · Selzentry / Celsentri

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Partial signal

NCT00098293 · Phase 3 · completed

This was a large, randomized, quadruple-blind, active-controlled trial comparing maraviroc with efavirenz, but its primary viral-load results were mixed rather than consistently meeting the prespecified non-inferiority margins. The primary endpoint was a virologic surrogate, and the once-daily maraviroc arm was terminated early after an interim analysis found that non-inferiority criteria were not met.

Next expected readout: March 2027 · NCT06805656 (registry estimate)

Reported efficacy

Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population; Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3% (mixed)

Result source: NCT00098293

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLeronlimabMaraviroc
HIV-1 RNA below 50 copies/mL (week 48)—Not reported41.8% vs 16.1%+25.7 vs placeboQD · wk 48 · n 232NCT00098306
16 other results
  • 46.8% vs 16.1% BID · wk 48 · n 235 · Phase 2/3 · secondary NCT00098306
  • 45.0% vs 17.6% QD · wk 48 · n 182 · Phase 2/3 · secondary NCT00098722
  • 44.5% vs 17.6% BID · wk 48 · n 191 · Phase 2/3 · secondary NCT00098722
  • 42.2% vs 24.6% QD · wk 24 · n 232 · Phase 2/3 · secondary NCT00098306
  • 48.5% vs 24.6% BID · wk 24 · n 235 · Phase 2/3 · secondary NCT00098306
  • 45.6% vs 20.9% QD · wk 24 · n 182 · Phase 2/3 · secondary NCT00098722
  • 40.8% vs 20.9% BID · wk 24 · n 191 · Phase 2/3 · secondary NCT00098722
  • 74.6% vs 83.6% wk 48 · n 59 · Phase 2 · primary NCT00827112
  • 67.8% vs 82.0% wk 96 · n 59 · Phase 2 · secondary NCT00827112
  • 76.3% vs 83.6% wk 84 · n 59 · Phase 2 · secondary NCT00827112
  • 74.6% vs 82.0% wk 72 · n 59 · Phase 2 · secondary NCT00827112
  • 67.8% vs 85.3% wk 60 · n 59 · Phase 2 · secondary NCT00827112
  • 74.6% vs 83.6% wk 48 · n 59 · Phase 2 · secondary NCT00827112
  • 81.4% vs 88.5% wk 40 · n 59 · Phase 2 · secondary NCT00827112
  • 79.7% vs 88.5% wk 32 · n 59 · Phase 2 · secondary NCT00827112
  • 81.4% vs 88.5% wk 24 · n 59 · Phase 2 · secondary NCT00827112
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported112.5 vs 54.0+58.6 vs placeboQD · wk 48 · n 227NCT00098306
19 other results
  • 122.4 vs 54.0 BID · wk 48 · n 233 · Phase 2/3 · secondary NCT00098306
  • 121.5 vs 69.3 QD · wk 48 · n 180 · Phase 2/3 · secondary NCT00098722
  • 127.8 vs 69.3 BID · wk 48 · n 185 · Phase 2/3 · secondary NCT00098722
  • 106.6 vs 52.1 QD · wk 24 · n 227 · Phase 2/3 · secondary NCT00098306
  • 111.1 vs 52.1 BID · wk 24 · n 233 · Phase 2/3 · secondary NCT00098306
  • 111.7 vs 63.8 QD · wk 24 · n 180 · Phase 2/3 · secondary NCT00098722
  • 101.9 vs 63.8 BID · wk 24 · n 185 · Phase 2/3 · secondary NCT00098722
  • 65.9 vs 51.3 QD · wk 48 · n 57 · Phase 2/3 · secondary NCT00098748
  • 78.9 vs 51.3 BID · wk 48 · n 52 · Phase 2/3 · secondary NCT00098748
  • 59.2 vs 36.4 QD · wk 24 · n 57 · Phase 2/3 · secondary NCT00098748
  • 62.7 vs 36.4 BID · wk 24 · n 52 · Phase 2/3 · secondary NCT00098748
  • 183.8 vs 171.5 Once daily, then twice daily · wk 96 · n 174 · Phase 3 · secondary NCT00098293
  • 206.3 vs 171.5 Twice daily · wk 96 · n 360 · Phase 3 · secondary NCT00098293
  • 172.5 vs 143.5 Once daily, then twice daily · wk 48 · n 174 · Phase 3 · secondary NCT00098293
  • 169.5 vs 143.5 Twice daily · wk 48 · n 360 · Phase 3 · secondary NCT00098293
  • 17 vs 17 wk 24 · n 22 · Phase 4 · secondary NCT00735072
  • 287.5 vs 298.5 wk 96 · n 59 · Phase 2 · secondary NCT00827112
  • 215.7 vs 226.6 wk 48 · n 59 · Phase 2 · secondary NCT00827112
  • 188.9 vs 173.3 wk 24 · n 59 · Phase 2 · secondary NCT00827112

HIV-1 RNA below 50 copies/mL (week 48)

Leronlimab
—Not reported
Maraviroc
41.8% vs 16.1%+25.7 vs placeboQD · wk 48 · n 232NCT00098306
16 other results
  • 46.8% vs 16.1% BID · wk 48 · n 235 · Phase 2/3 · secondary NCT00098306
  • 45.0% vs 17.6% QD · wk 48 · n 182 · Phase 2/3 · secondary NCT00098722
  • 44.5% vs 17.6% BID · wk 48 · n 191 · Phase 2/3 · secondary NCT00098722
  • 42.2% vs 24.6% QD · wk 24 · n 232 · Phase 2/3 · secondary NCT00098306
  • 48.5% vs 24.6% BID · wk 24 · n 235 · Phase 2/3 · secondary NCT00098306
  • 45.6% vs 20.9% QD · wk 24 · n 182 · Phase 2/3 · secondary NCT00098722
  • 40.8% vs 20.9% BID · wk 24 · n 191 · Phase 2/3 · secondary NCT00098722
  • 74.6% vs 83.6% wk 48 · n 59 · Phase 2 · primary NCT00827112
  • 67.8% vs 82.0% wk 96 · n 59 · Phase 2 · secondary NCT00827112
  • 76.3% vs 83.6% wk 84 · n 59 · Phase 2 · secondary NCT00827112
  • 74.6% vs 82.0% wk 72 · n 59 · Phase 2 · secondary NCT00827112
  • 67.8% vs 85.3% wk 60 · n 59 · Phase 2 · secondary NCT00827112
  • 74.6% vs 83.6% wk 48 · n 59 · Phase 2 · secondary NCT00827112
  • 81.4% vs 88.5% wk 40 · n 59 · Phase 2 · secondary NCT00827112
  • 79.7% vs 88.5% wk 32 · n 59 · Phase 2 · secondary NCT00827112
  • 81.4% vs 88.5% wk 24 · n 59 · Phase 2 · secondary NCT00827112

HIV-1 RNA 50 copies/mL or more (week 48)

Leronlimab
—Not reported
Maraviroc
—Not reported

CD4 count, change (week 48)

Leronlimab
—Not reported
Maraviroc
112.5 vs 54.0+58.6 vs placeboQD · wk 48 · n 227NCT00098306
19 other results
  • 122.4 vs 54.0 BID · wk 48 · n 233 · Phase 2/3 · secondary NCT00098306
  • 121.5 vs 69.3 QD · wk 48 · n 180 · Phase 2/3 · secondary NCT00098722
  • 127.8 vs 69.3 BID · wk 48 · n 185 · Phase 2/3 · secondary NCT00098722
  • 106.6 vs 52.1 QD · wk 24 · n 227 · Phase 2/3 · secondary NCT00098306
  • 111.1 vs 52.1 BID · wk 24 · n 233 · Phase 2/3 · secondary NCT00098306
  • 111.7 vs 63.8 QD · wk 24 · n 180 · Phase 2/3 · secondary NCT00098722
  • 101.9 vs 63.8 BID · wk 24 · n 185 · Phase 2/3 · secondary NCT00098722
  • 65.9 vs 51.3 QD · wk 48 · n 57 · Phase 2/3 · secondary NCT00098748
  • 78.9 vs 51.3 BID · wk 48 · n 52 · Phase 2/3 · secondary NCT00098748
  • 59.2 vs 36.4 QD · wk 24 · n 57 · Phase 2/3 · secondary NCT00098748
  • 62.7 vs 36.4 BID · wk 24 · n 52 · Phase 2/3 · secondary NCT00098748
  • 183.8 vs 171.5 Once daily, then twice daily · wk 96 · n 174 · Phase 3 · secondary NCT00098293
  • 206.3 vs 171.5 Twice daily · wk 96 · n 360 · Phase 3 · secondary NCT00098293
  • 172.5 vs 143.5 Once daily, then twice daily · wk 48 · n 174 · Phase 3 · secondary NCT00098293
  • 169.5 vs 143.5 Twice daily · wk 48 · n 360 · Phase 3 · secondary NCT00098293
  • 17 vs 17 wk 24 · n 22 · Phase 4 · secondary NCT00735072
  • 287.5 vs 298.5 wk 96 · n 59 · Phase 2 · secondary NCT00827112
  • 215.7 vs 226.6 wk 48 · n 59 · Phase 2 · secondary NCT00827112
  • 188.9 vs 173.3 wk 24 · n 59 · Phase 2 · secondary NCT00827112
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Leronlimab: 7 of 8 rows · Maraviroc: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLeronlimab
Rows use multiple source trials
Maraviroc
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
7.6 cells/uL700 mg Weekly Injectionsa,b,c,d,e
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 2 more doses
-7.4 cells/uL525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
-41.1 cells/uL350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
93 cells/uL @ 144wkb,c,d,e
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
HIV-1 RNA
absolute change · log
Induction
0.6 vs 0.1 placebo log @ 1wkf,c,g,h
NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3
-89859.1 vs -107684.6 Atazanavir / Ritonavir + Emtricitabine / Tenofovir log @ 16wkf,c,g,h
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA
absolute change · log
No placebo or comparator arm
2.4 log @ 25wkb,c,i,j
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
1 other source trial
-1.78 log350 mg weekly SQ
NCT02175680 · Phase 2 · registry result, not featured evidence
-1.5 log @ 84wkb,c,i,j
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy
Time to Virologic Failure
time to event · months
No placebo or comparator arm
2.32 months*350 mgk,c,l,e
NCT02175680 · Phase 2 · registry result, not featured evidence · converted to months from 70.71 days as posted
8.38 months*k,c,l,e
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy · converted to months from 255 days as posted
1 other source trial
2.84 months*
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy · converted to months from 86.5 days as posted
Dropout rate
—700 mg Weekly Injectionsm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 13 more results
—525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—Part 2 - Group A
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—Part 2 - Group B
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
0%PRO 140
NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3
—Part 2 PRO 140 Open Label for 24 W
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
—weekly for 1 week
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
4.7%350 mg weekly SQ
NCT02175680 · Phase 2 · registry result, not featured evidence
—Leronlimab
NCT02175680 · Phase 2 · registry result, not featured evidence
0%PRO 140 Dose 1
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 2
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 3
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 4
NCT00110591 · Phase 1 · registry result, not featured evidence
—Once daily, then twice dailyn
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 29 more results
45.1%Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
—Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
n/a: no completion milestoneBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
n/a: no completion milestoneQD
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—
NCT02881762 · Phase 4 · registry result, not featured evidence
0%
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
0%
NCT00925756 · Phase 4 · registry result, not featured evidence
16.9%
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
27.3%Maraviroc PLUS Raltegravir in Comb
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Maraviroc in Combination With 2 NR
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
4.3%
NCT00735072 · Phase 4 · registry result, not featured evidence
28.6%
NCT01896921 · Phase 3 · registry result, not featured evidence · combination
7.7%
NCT00844519 · Phase 3 · registry result, not featured evidence
40.2%
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy
12.5%
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
12.5%
NCT01154673 · Phase 2/3 · registry result, not featured evidence
—BID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
—QD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
3.2%BID
NCT00098748 · Phase 2/3 · registry result, not featured evidence
0%QD
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
12.2%
NCT02741323 · Phase 2 · registry result, not featured evidence
46.2%
NCT01276236 · Phase 2 · registry result, not featured evidence
20%
NCT00987948 · Phase 2 · registry result, not featured evidence
12%
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
6.7%
NCT01894776 · Phase 1 · registry result, not featured evidence
7.7%
NCT00982878 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—700 mg Weekly Injectionsm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 13 more results
—525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—Part 2 - Group A
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—Part 2 - Group B
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—PRO 140
NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3
—Part 2 PRO 140 Open Label for 24 W
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
—weekly for 1 week
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
—350 mg weekly SQ
NCT02175680 · Phase 2 · registry result, not featured evidence
—Leronlimab
NCT02175680 · Phase 2 · registry result, not featured evidence
—PRO 140 Dose 1
NCT00110591 · Phase 1 · registry result, not featured evidence
—PRO 140 Dose 2
NCT00110591 · Phase 1 · registry result, not featured evidence
—PRO 140 Dose 3
NCT00110591 · Phase 1 · registry result, not featured evidence
—PRO 140 Dose 4
NCT00110591 · Phase 1 · registry result, not featured evidence
—Once daily, then twice dailyn
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 29 more results
7.3%Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
—Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
4.2%BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
4.6%QD
NCT00098306 · Phase 2/3 · HIV · phase 2/3
—
NCT02881762 · Phase 4 · registry result, not featured evidence
—
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT00925756 · Phase 4 · registry result, not featured evidence
5.2%
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
—Maraviroc PLUS Raltegravir in Comb
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—Maraviroc in Combination With 2 NR
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—
NCT00735072 · Phase 4 · registry result, not featured evidence
—
NCT01896921 · Phase 3 · registry result, not featured evidence · combination
3.8%
NCT00844519 · Phase 3 · registry result, not featured evidence
2.4%
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy
2.2%
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
—
NCT01154673 · Phase 2/3 · registry result, not featured evidence
—BID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
—QD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
—BID
NCT00098748 · Phase 2/3 · registry result, not featured evidence
—QD
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
—
NCT02741323 · Phase 2 · registry result, not featured evidence
—
NCT01276236 · Phase 2 · registry result, not featured evidence
—
NCT00987948 · Phase 2 · registry result, not featured evidence
—
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
3.1%
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
—
NCT01894776 · Phase 1 · registry result, not featured evidence
—
NCT00982878 · Phase 1 · registry result, not featured evidence
Serious AEs
5.3%700 mg Weekly Injectionsm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 13 more results
5.9%525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
7.1%350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
5.8%Part 2 - Group A
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
4.6%Part 2 - Group B
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
—PRO 140
NCT02483078 · Phase 2/3 · background therapy · HIV · phase 2/3
15.4%Part 2 PRO 140 Open Label for 24 W
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
0%weekly for 1 week
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
—350 mg weekly SQ
NCT02175680 · Phase 2 · registry result, not featured evidence
2.3%Leronlimab
NCT02175680 · Phase 2 · registry result, not featured evidence
25%PRO 140 Dose 1
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 2
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 3
NCT00110591 · Phase 1 · registry result, not featured evidence
0%PRO 140 Dose 4
NCT00110591 · Phase 1 · registry result, not featured evidence
27%Once daily, then twice dailyn
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 29 more results
21.4%Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
3.1%Twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
22.6%BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
0%BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
10.1%BID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
18.1%QD
NCT00098306 · Phase 2/3 · HIV · phase 2/3
11.1%
NCT02881762 · Phase 4 · registry result, not featured evidence
0%
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
3.1%
NCT00925756 · Phase 4 · registry result, not featured evidence
2.6%
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
0%Maraviroc PLUS Raltegravir in Comb
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Maraviroc in Combination With 2 NR
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00735072 · Phase 4 · registry result, not featured evidence
42.9%
NCT01896921 · Phase 3 · registry result, not featured evidence · combination
3.8%
NCT00844519 · Phase 3 · registry result, not featured evidence
16.5%
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy
13.5%
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
6.3%
NCT01154673 · Phase 2/3 · registry result, not featured evidence
24.1%BID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
22%QD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
22.6%BID
NCT00098748 · Phase 2/3 · registry result, not featured evidence
20.6%QD
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
75.5%
NCT02741323 · Phase 2 · registry result, not featured evidence
0%
NCT01276236 · Phase 2 · registry result, not featured evidence
6.7%
NCT00987948 · Phase 2 · registry result, not featured evidence
0%
NCT00993148 · Phase 2 · registry result, not featured evidence · combination
21.7%
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01894776 · Phase 1 · registry result, not featured evidence
0%
NCT00982878 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
700 mg Weekly Injectionsm
upper respiratory tract infection 6.9%
headache 4.6%
diarrhoea 3.8%
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 11 more results
525 mg Weekly Injections
upper respiratory tract infection 6.8%
diarrhoea 4.4%
headache 4.4%
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
350 mg Weekly Injections
diarrhoea 8.8%
upper respiratory tract infection 8.8%
fatigue 8.4%
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
upper respiratory tract infection 17.4%
viral upper respiratory tract infection 14.5%
diarrhoea 8.7%
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
upper respiratory tract infection 18.5%
diarrhoea 9.2%
headache 7.7%
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
diarrhoea 11.5% (placebo 0%)
arthralgia 9.6% (placebo 0%)
injection site haemorrhage 9.6% (placebo 3.7%)
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
weekly for 1 week
fatigue 4% (placebo 0%)
nausea 4% (placebo 0%)
abdominal pain 0% (placebo 0%)
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3
diarrhoea 9.3%
fatigue 9.3%
injection site pruritus 9.3%
NCT02175680 · Phase 2 · registry result, not featured evidence
back pain 25% (placebo 25%)
cough 25% (placebo 0%)
electrocardiogram t wave inversion 25% (placebo 0%)
NCT00110591 · Phase 1 · registry result, not featured evidence
abdominal pain upper 0% (placebo 0%)
alanine aminotransferase increased 0% (placebo 25%)
aspartate aminotransferase increased 0% (placebo 50%)
NCT00110591 · Phase 1 · registry result, not featured evidence
pharyngolaryngeal pain 75% (placebo 0%)
headache 50% (placebo 25%)
abdominal pain upper 25% (placebo 0%)
NCT00110591 · Phase 1 · registry result, not featured evidence
high creatine phosphokinase level 50% (placebo 50%)
cough 25% (placebo 0%)
dizziness 25% (placebo 0%)
NCT00110591 · Phase 1 · registry result, not featured evidence
Once daily, then twice dailyn
nausea 34.5%
diarrhoea 26.4%
headache 25.3%
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 22 more results
Twice daily
nausea 38.3%
headache 30.3%
diarrhoea 25%
NCT00098293 · Phase 3 · combination · HIV · phase 3
Twice daily
abdominal distension 0%
abdominal pain 0%
abdominal pain upper 0%
NCT00098293 · Phase 3 · combination · HIV · phase 3
BID
diarrhoea 22.6% (placebo 25.4%)
nausea 20.4% (placebo 19.5%)
fatigue 19.6% (placebo 18.6%)
NCT00098306 · Phase 2/3 · HIV · phase 2/3
BID
abdominal distension 0% (placebo 3.4%)
abdominal pain 0% (placebo 0.8%)
arthralgia 0% (placebo 2.5%)
NCT00098306 · Phase 2/3 · HIV · phase 2/3
BID
upper respiratory tract infection 5.8% (placebo 8.5%)
abdominal distension 0% (placebo 3.4%)
abdominal pain 0% (placebo 0.8%)
NCT00098306 · Phase 2/3 · HIV · phase 2/3
QD
diarrhoea 25% (placebo 25.4%)
nausea 19.4% (placebo 19.5%)
fatigue 15.5% (placebo 18.6%)
NCT00098306 · Phase 2/3 · HIV · phase 2/3
presyncope 11.1% (placebo 0%)
soft tissue injury 11.1% (placebo 0%)
vomiting 11.1% (placebo 0%)
NCT02881762 · Phase 4 · registry result, not featured evidence
skin infection 22.2%
upper respiratory infection 22.2%
cerebrospinal fluid leakage 11.1%
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
nausea 11.7%
respiratory tract infection 11.7%
malaise 10.4%
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 9.1%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 0%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
indirect hyperbilirubinemia (on atazanavir-based art) 8.7% (placebo 4.5%)
prolonged fever 4.3% (placebo 0%)
triglyceride elevation 4.3% (placebo 0%)
NCT00735072 · Phase 4 · registry result, not featured evidence
diarrhoea 16%
nasopharyngitis 15.5%
headache 10.7%
NCT00478231 · Phase 3 · registry result, not featured evidence · background therapy
diarrhoea 9.1%
bronchitis 6.5%
headache 6.4%
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
BID
diarrhoea 20.4% (placebo 20.9%)
nausea 17.3% (placebo 18.7%)
headache 15.7% (placebo 17.6%)
NCT00098722 · Phase 2/3 · registry result, not featured evidence
QD
diarrhoea 26.9% (placebo 20.9%)
nausea 21.4% (placebo 18.7%)
headache 19.8% (placebo 17.6%)
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
BID
injection site reaction 21% (placebo 14.8%)
diarrhoea 19.4% (placebo 21.3%)
headache 17.7% (placebo 8.2%)
NCT00098748 · Phase 2/3 · registry result, not featured evidence
QD
diarrhoea 28.6% (placebo 21.3%)
headache 20.6% (placebo 8.2%)
nausea 14.3% (placebo 19.7%)
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
haemoglobin decreased 28.6% (placebo 22.9%)
blood creatinine increased 24.5% (placebo 14.6%)
blood glucose increased 16.3% (placebo 12.5%)
NCT02741323 · Phase 2 · registry result, not featured evidence
fatigue 30.8%
cough 23.1%
diarrhea 15.4%
NCT01276236 · Phase 2 · registry result, not featured evidence
hyperbilirubinaemia 30%
diarrhoea 25%
ocular icterus 21.7%
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
headache 42.9%
fever 14.3%
joint pain 14.3%
NCT01894776 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: background therapy versus monotherapy.
  5. eThe assessment timepoint is not available for both results.
  6. fTrial phases differ: Phase 2 versus Phase 2/3.
  7. gTreatment context differs: combination versus background therapy.
  8. hAssessment timepoints differ: 16 weeks versus 1 weeks.
  9. iTreatment context differs: background therapy versus combination.
  10. jAssessment timepoints differ: 84 weeks versus 25 weeks.
  11. kTrial phases differ: Phase 3 versus Phase 2.
  12. lTreatment context has not been resolved for both arms.
  13. mPopulation comparability has not been reviewed for 6 of these studies.
  14. nPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Leronlimab

Virologic Failure Free 0.45% (n=131) @ 48wk700 mg Weekly Injections
event count · % of participants
No placebo or comparator arm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 2 more results
0.43% (n=205) @ 48wk525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
0.23% (n=226) @ 48wk350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
Virologic Failure 0.41% (n=131) @ 48wk700 mg Weekly Injections
event count · % of participants
No placebo or comparator arm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 3 more results
0.42% (n=205) @ 48wk525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
0.66% (n=226) @ 48wk350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
0.439% (n=41) @ 14wk350 mg
NCT02175680 · Phase 2 · registry result, not featured evidence
Time to Confirmed Virologic Failure 6.59 months700 mg Weekly Injections
time to event · months
No placebo or comparator arm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 · converted to months from 200.6 days as posted
show 2 more results
6.5 months*525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 · converted to months from 197.7 days as posted
4.5 months*350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3 · converted to months from 136.9 days as posted
HIV-1 RNA Suppression 0.41% (n=131) @ 48wk700 mg Weekly Injections
event count · % of participants
No placebo or comparator arm
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
show 2 more results
0.54% (n=205) @ 48wk525 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
0.33% (n=226) @ 48wk350 mg Weekly Injections
NCT02859961 · Phase 2/3 · monotherapy · HIV · phase 2/3
HIV-1 RNA Less Than 400 Copies Per 71.2% (n=52) @ 25wk
event count · % of participants
No placebo or comparator arm
With HIV-1 RNA < 400 Copies/mL at Week 25
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 · converted to % from 37 Participants as posted
HIV-1 RNA Less Than 50 Copies 61.5% (n=52) @ 25wk
event count · % of participants
No placebo or comparator arm
With HIV-1 RNA < 50 Copies/mL at Week 25
NCT02483078 · Phase 2/3 · combination · HIV · phase 2/3 · converted to % from 32 Participants as posted
HIV-1 RNA 0.1 log @ 2wk
absolute change · log
No placebo or comparator arm
T2 (Week 2)
NCT02175680 · Phase 2 · registry result, not featured evidence
HIV-1 RNA 0.01 log @ 3wk
absolute change · log
No placebo or comparator arm
T3 (Week 3)
NCT02175680 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -0.13 log @ 4wk
absolute change · log
No placebo or comparator arm
T4 (Week 4)
NCT02175680 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -0.25 log @ 5wk
absolute change · log
No placebo or comparator arm
T5 (Week 5)
NCT02175680 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -0.76 log @ 6wk
absolute change · log
No placebo or comparator arm
T6 (Week 6)
NCT02175680 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -0.88 log @ 7wk
absolute change · log
No placebo or comparator arm
T7 (Week 7)
NCT02175680 · Phase 2 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

Maraviroc

HIV-1 RNA Less Than 400 Copies 61.5% (n=174) vs 73.1% (n=361) Efavirenz @ 48wkOnce daily, then twice daily
responder rate · % of participants
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 7 more results
70.6% (n=360) vs 73.1% (n=361) Efavirenz @ 48wkTwice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
61.5% (n=174) vs 73.1% (n=361) Efavirenz @ 48wkOnce daily, then twice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
70.6% (n=360) vs 73.1% (n=361) Efavirenz @ 48wkTwice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
52.9% (n=174) vs 64.5% (n=361) Efavirenz @ 96wkOnce daily, then twice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
61.4% (n=360) vs 64.5% (n=361) Efavirenz @ 96wkTwice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
52.9% (n=174) vs 64.5% (n=361) Efavirenz @ 96wkOnce daily, then twice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
61.4% (n=360) vs 64.5% (n=361) Efavirenz @ 96wkTwice daily
Less than 400 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 50 Copies 55.8% (n=174) vs 69.3% (n=361) Efavirenz @ 48wkOnce daily, then twice daily
responder rate · % of participants
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 7 more results
65.3% (n=360) vs 69.3% (n=361) Efavirenz @ 48wkTwice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
55.8% (n=174) vs 69.3% (n=361) Efavirenz @ 48wkOnce daily, then twice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
65.3% (n=360) vs 69.3% (n=361) Efavirenz @ 48wkTwice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
48.3% (n=174) vs 62.6% (n=361) Efavirenz @ 96wkOnce daily, then twice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
56.9% (n=360) vs 62.6% (n=361) Efavirenz @ 96wkTwice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
48.3% (n=174) vs 62.6% (n=361) Efavirenz @ 96wkOnce daily, then twice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
56.9% (n=360) vs 62.6% (n=361) Efavirenz @ 96wkTwice daily
Less than 50 copies/mL
NCT00098293 · Phase 3 · combination · HIV · phase 3
CD4+ 172.5 vs 143.52 Efavirenz cells/uL @ 48wkOnce daily, then twice daily
absolute change · cells/uL
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 20 more results
169.53 vs 143.52 Efavirenz cells/uL @ 48wkTwice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
183.75 vs 171.5 Efavirenz cells/uL @ 96wkOnce daily, then twice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
206.31 vs 171.5 Efavirenz cells/uL @ 96wkTwice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
106.63 vs 52.14 placebo cells/uL @ 24wkQD
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
111.08 vs 52.14 placebo cells/uL @ 24wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
112.53 vs 53.97 placebo cells/uL @ 48wkQD
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
122.44 vs 53.97 placebo cells/uL @ 48wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
17 vs 17 placebo cells/uL @ 24wk
NCT00735072 · Phase 4 · registry result, not featured evidence
111.72 vs 63.78 placebo cells/uL @ 24wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
101.89 vs 63.78 placebo cells/uL @ 24wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
121.49 vs 69.34 placebo cells/uL @ 48wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
127.8 vs 69.34 placebo cells/uL @ 48wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
59.237 vs 36.367 placebo cells/uL @ 24wkQD
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
62.651 vs 36.367 placebo cells/uL @ 24wkBID
NCT00098748 · Phase 2/3 · registry result, not featured evidence
65.86 vs 51.29 placebo cells/uL @ 48wkQD
NCT00098748 · Phase 2/3 · registry result, not featured evidence · background therapy
78.87 vs 51.29 placebo cells/uL @ 48wkBID
NCT00098748 · Phase 2/3 · registry result, not featured evidence
169.6 vs 139.8 Atazanavir / Ritonavir + Emtricitabine / Tenofovir cells/uL @ 16wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
188.9 vs 173.3 Atazanavir / Ritonavir + Emtricitabine / Tenofovir cells/uL @ 24wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
215.7 vs 226.6 Atazanavir / Ritonavir + Emtricitabine / Tenofovir cells/uL @ 48wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
287.5 vs 298.5 Atazanavir / Ritonavir + Emtricitabine / Tenofovir cells/uL @ 96wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
Time to Confirmed Virologic Failure NA vs NA Efavirenz months @ 48wkTwice daily
time to event · months
NCT00098293 · Phase 3 · combination · HIV · phase 3
show 1 more result
NA vs NA Efavirenz months @ 96wkTwice daily
NCT00098293 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 400 Copies 54.7% (n=232) vs 31.4% (n=118) placebo @ 24wkQD
responder rate · % of participants
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
show 21 more results
60.4% (n=235) vs 31.4% (n=118) placebo @ 24wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
50.9% (n=232) vs 22% (n=118) placebo @ 48wkQD
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
57.5% (n=235) vs 22% (n=118) placebo @ 48wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
55.49% (n=182) vs 23.08% (n=91) placebo @ 24wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
61.26% (n=191) vs 23.08% (n=91) placebo @ 24wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
52.75% (n=182) vs 23.08% (n=91) placebo @ 48wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
54.97% (n=191) vs 23.08% (n=91) placebo @ 48wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
27.12% (n=59) vs 34.43% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 2wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
50.85% (n=59) vs 52.46% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 4wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
79.66% (n=59) vs 77.05% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 8wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
89.83% (n=59) vs 88.52% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 12wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
88.14% (n=59) vs 91.8% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 16wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
89.83% (n=59) vs 93.44% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 20wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
91.53% (n=59) vs 93.44% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 24wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
89.83% (n=59) vs 93.44% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 32wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
91.53% (n=59) vs 90.16% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 40wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
89.83% (n=59) vs 86.89% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 48wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
86.44% (n=59) vs 86.89% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 60wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
86.44% (n=59) vs 85.25% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 72wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
81.36% (n=59) vs 85.25% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 84wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
77.97% (n=59) vs 83.61% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 96wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 42.2% (n=232) vs 24.6% (n=118) placebo @ 24wkQD
responder rate · % of participants
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
show 22 more results
48.5% (n=235) vs 24.6% (n=118) placebo @ 24wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
41.8% (n=232) vs 16.1% (n=118) placebo @ 48wkQD
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3
46.8% (n=235) vs 16.1% (n=118) placebo @ 48wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
45.6% (n=182) vs 20.88% (n=91) placebo @ 24wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
40.84% (n=191) vs 20.88% (n=91) placebo @ 24wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
45.05% (n=182) vs 17.58% (n=91) placebo @ 48wkQD
NCT00098722 · Phase 2/3 · registry result, not featured evidence · background therapy
44.5% (n=191) vs 17.58% (n=91) placebo @ 48wkBID
NCT00098722 · Phase 2/3 · registry result, not featured evidence
74.6% (n=59) vs 83.6% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 48wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
0% (n=59) vs 6.6% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 2wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
8.5% (n=59) vs 21.3% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 4wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
47.5% (n=59) vs 42.6% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 8wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
61% (n=59) vs 62.3% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 12wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
72.9% (n=59) vs 73.8% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 16wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
71.2% (n=59) vs 83.61% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 20wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
81.36% (n=59) vs 88.52% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 24wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
79.66% (n=59) vs 88.52% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 32wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
81.36% (n=59) vs 88.52% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 40wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
74.58% (n=59) vs 83.61% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 48wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
67.8% (n=59) vs 85.25% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 60wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
74.58% (n=59) vs 81.97% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 72wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
76.27% (n=59) vs 83.61% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 84wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
67.8% (n=59) vs 81.97% (n=61) Atazanavir / Ritonavir + Emtricitabine / Tenofovir @ 96wk
NCT00827112 · Phase 2 · registry result, not featured evidence · combination
Time to Virological Failure 11.3 vs 0 placebo months @ 48wkQD
time to event · months
NCT00098306 · Phase 2/3 · background therapy · HIV · phase 2/3 · converted to months from 344 days as posted
show 1 more result
NA vs 0 placebo months @ 48wkBID
NCT00098306 · Phase 2/3 · HIV · phase 2/3
HCV RNA 47231 vs -811264 placebo uIU/mL @ 4wk
absolute change · uIU/mL
Change in HCV viral load at 4 weeks
NCT02881762 · Phase 4 · registry result, not featured evidence
HCV RNA 2138768 uIU/mL @ 1wk
absolute change · uIU/mL
No placebo or comparator arm
NCT02881762 · Phase 4 · registry result, not featured evidence
Neurocognitive Composite -0.51 vs -1.03 Standard of Care HAART Regimen Z-score @ 26wk
absolute change · Z-score
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
show 1 more result
-0.56 vs -0.93 Standard of Care HAART Regimen Z-score @ 52wk
NCT01449006 · Phase 4 · registry result, not featured evidence · background therapy
HIV-1 RNA Less Than 50 Copies 77.92% (n=77) @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
show 25 more results
7.79% (n=77) @ 4wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
26.67% (n=77) @ 8wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
48.68% (n=77) @ 12wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
78.08% (n=77) @ 20wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
83.56% (n=77) @ 24wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
89.71% (n=77) @ 36wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
92.31% (n=77) @ 48wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
19.9% (n=1032) @ 2wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
30.1% (n=1032) @ 4wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
43.1% (n=1032) @ 8wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
45.8% (n=1032) @ 12wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
37.4% (n=1032) @ 16wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
42.7% (n=1032) @ 20wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
55.8% (n=1032) @ 24wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
57.4% (n=1032) @ 32wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
54.6% (n=1032) @ 40wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
54.8% (n=1032) @ 48wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
51.9% (n=1032) @ 60wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
49.6% (n=1032) @ 72wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
55.7% (n=1032) @ 84wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
54.2% (n=1032) @ 96wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
77.8% (n=1032) @ 108wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
44.4% (n=1032) @ 120wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
75% (n=1032) @ 132wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
100% (n=1032) @ 144wk
NCT00426660 · Phase 3 · registry result, not featured evidence · background therapy
HIV-1 RNA Less Than 400 41.56% (n=77) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
show 6 more results
72% (n=77) @ 8wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
89.47% (n=77) @ 12wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
91.78% (n=77) @ 20wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
91.78% (n=77) @ 24wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
97.06% (n=77) @ 36wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination
95.38% (n=77) @ 48wk
NCT01275625 · Phase 4 · registry result, not featured evidence · combination

+ 45 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Leronlimab's landscape · Maraviroc's landscape